ENDPOINTS NEWS2h
23and­Me's CEO sub­mits bid to take com­pa­ny pri­vate for $74.7M
Me CEO Anne Wojcicki and New Mountain Capital propose $2.53/share buyout to take company private, valuing it at $74.7M after ...
ENDPOINTS NEWS4h
Am­gen plans fur­ther $200M in­vest­ment in new tech fa­cil­i­ty in In­dia
Amgen to invest $200M in new Hyderabad tech center through 2025, focusing on AI for drug development. Site opened Monday with ...
ENDPOINTS NEWS3h
FDA lifts hold on En­trada's Duchenne drug af­ter two years
Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...
ENDPOINTS NEWS6h
Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion
Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...
ENDPOINTS NEWS7h
Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos
With help from its $43 billion Seagen merger, Pfizer will contribute its antibody-drug conjugates to Summit Therapeutics' ...
ENDPOINTS NEWS8h
How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try
So far, only 22% of life sciences organizations have adopted AI at scale, yet 86% of healthcare and life sciences leaders ...
ENDPOINTS NEWS3h
FDA won’t al­low In­vivyd’s Pem­gar­da to treat Covid; An­tibi­ot­ic biotech launch­es
FDA denies Invivyd's EUA expansion for Pemgarda in Covid treatment while BioCryst reports positive Orladeyo data. AN2 changes endpoint, OS Therapies seeks partners & Eyenovia restructures.